---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-013687"
form_type: "8-K"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2024-04-29T23:59:59+00:00"
generated_at: "2026-06-03T05:32:26.206154+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ekso Bionics Q1 revenue $3.8M; net loss narrows; CMS Medicare reimbursement for Indego Personal

## Summary
- Revenue $3.8M (down 7% YoY from $4.1M); gross margin improved to 52% from 49%.
- Net loss narrowed to $3.4M ($0.20 per share) compared to $4.4M ($0.33) in Q1 2023.
- CMS issued final Medicare payment determination for Ekso Indego Personal, enabling reimbursement.
- Sold 29 EksoHealth units in Q1; cash and restricted cash $8.8M at March 31, 2024.

## SEC filing metadata
- accession: 0001437749-24-013687
- form_type: 8-K
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2024-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000143774924013687/0001437749-24-013687-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000143774924013687/ekso20240425_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-013687
- JSON: https://secwatch.observer/filing/0001437749-24-013687.json
- Plain text: https://secwatch.observer/filing/0001437749-24-013687.txt

## Key facts
- Earnings Releases
  EKSO BIONICS HOLDINGS, INC. reported three months ended March 31, 2024 results: revenue $3.8 million, net income $3.4 million, EPS $0.20 per basic and diluted share.
  - Period: three months ended March 31, 2024
  - Revenue: $3.8 million
  - Net income: $3.4 million
  - EPS: $0.20 per basic and diluted share
  - Result: reported results
  source text: ● Received final payment determination for Medicare reimbursement from the Centers for Medicare & Medicaid Services (“CMS”) for Ekso Indego Personal ● Reported revenues of $3.8 million for the first quarter of 2024 ● Achieved gross margin of 52% for the quarter ended March 31, 2024 ● Sold a total of 29 EksoHealth units in the first quarter of 2024 “We started
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549084/000143774924013687/0001437749-24-013687-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.